3 Pathology Network, Group Holding Company and FMCG Major Stocks With a Strong Future Roadmap: Suraksha Diagnostic, Godrej Industries and ITC
- October 16, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Suraksha Diagnostic Rs 307.65, P/E 46.05. Godrej Industries Rs 1,030.50, P/E 15.29. ITC Rs 263.90, P/E 15.77. Closing prices of 14 Oct 2026.
Quick Answer
Pathology network, group holding company and FMCG major stocks with the clearest long-term roadmaps today include Suraksha Diagnostic in diagnostic and pathology testing through a network of labs and collection centres, Godrej Industries in chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm and ITC in cigarettes, packaged foods, personal care, paperboards, hotels and agri products. FY26 revenue growth was 22.5% at Suraksha Diagnostic, 18.5% at Godrej Industries and 4.4% at ITC. P/E stands at 46.05 for Suraksha Diagnostic (industry 62.79), 15.29 for Godrej Industries (industry 36.60) and 15.77 for ITC (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Pathology network, group holding company and FMCG major stocks give investors exposure to health tests, group businesses and consumer goods used every day. Volumes, lab additions and margins decide how much of that demand turns into profit.
This list covers three pathology network, group holding company and FMCG major stocks: Suraksha Diagnostic for diagnostic and pathology testing through a network of labs and collection centres, Godrej Industries for chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm and ITC for cigarettes, packaged foods, personal care, paperboards, hotels and agri products. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pathology Network, Group Holding Company and FMCG Major Stocks?
Pathology network, group holding company and FMCG major stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Pathology Network, Group Holding Company and FMCG Major Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three pathology network, group holding company and FMCG major stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE |
|---|---|---|---|---|---|
| Suraksha Diagnostic | 307.65 | 1,614 | 46.05 | 62.79 | 13.15% |
| Godrej Industries | 1,030.50 | 33,784 | 15.29 | 36.60 | 11.10% |
| ITC | 263.90 | 318,338 | 15.77 | 34.85 | 28.53% |
Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Pathology Network, Group Holding Company and FMCG Major Stocks Have a Strong Roadmap in India?
Pathology network, group holding company and FMCG major stocks have a strong roadmap in India because preventive health checks, diversified group earnings and wider consumer brands keep adding volumes for these firms. Three drivers stand out.
- Preventive health: Families test more often and earlier.
- Group strength: Chemicals and listed stakes spread earnings across sectors.
- Brand spread: Packaged foods and personal care reach more homes.
Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline
Suraksha Diagnostic’s roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.
Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.
Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.
Godrej Industries: Chemicals and Group Holdings Build the Next Leg
Godrej Industries’ roadmap rests on chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm, with its chemical business and holdings in other group companies widening the earnings base.
Revenue grew from Rs 15,064.67 crore in FY22 to Rs 25,980.60 crore in FY26, a 72.5% rise, and FY26 revenue was 18.5% higher than FY25. FY26 net profit rose 29.8% to Rs 2,411.91 crore. Over four years, net profit rose from Rs 992.43 crore in FY22 to Rs 2,411.91 crore. In Q1 FY27, revenue grew 11.2% to Rs 6,360.30 crore. Operating margin was 26.91% in FY26.
Return on equity is 11.10%. At a P/E of 15.29 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: The P/E of 15.29 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
ITC: Several Businesses Anchor the Roadmap
ITC’s roadmap rests on cigarettes, packaged foods, personal care, paperboards, hotels and agri products, with several businesses supporting steady cash flow.
Revenue grew from Rs 62,504.44 crore in FY22 to Rs 81,294.27 crore in FY26, a 30.1% rise, and FY26 revenue was 4.4% higher than FY25. FY26 net profit rose 4.9% to Rs 21,018.15 crore. Over four years, net profit rose from Rs 15,503.13 crore in FY22 to Rs 21,018.15 crore. In Q1 FY27, revenue grew 26.7% to Rs 30,179.01 crore. Operating margin was 33.18% in FY26.
Debt to equity is 0.03 and return on equity is 28.53%. FY26 operating cash flow was Rs 18,464.31 crore against capital expenditure of Rs 2,182.89 crore. At a P/E of 15.77 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 15.77 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Pathology Network, Group Holding Company and FMCG Major Stocks in India: Suraksha Diagnostic vs Godrej Industries vs ITC on Key Financials
Among the best pathology network, group holding company and FMCG major stocks in India, Suraksha Diagnostic leads on FY26 revenue growth; Godrej Industries leads on FY26 net profit growth and the lowest P/E; ITC leads on FY26 operating margin and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | Suraksha Diagnostic | Godrej Industries | ITC |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 313.58 | 25,980.60 | 81,294.27 |
| FY26 revenue growth | 22.5% | 18.5% | 4.4% |
| FY26 net profit (Rs Cr) | 31.40 | 2,411.91 | 21,018.15 |
| FY26 net profit growth | 1.4% | 29.8% | 4.9% |
| FY26 operating profit margin | 32.01% | 26.91% | 33.18% |
| Q1 FY27 revenue growth (YoY) | 20.7% | 11.2% | 26.7% |
| Return on equity | 13.15% | 11.10% | 28.53% |
| P/E ratio | 46.05 | 15.29 | 15.77 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Pathology Network, Group Holding Company and FMCG Major Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen pathology network, group holding company and FMCG major stocks and shortlist pathology network, group holding company and FMCG major stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Pathology Network, Group Holding Company and FMCG Major Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic, Godrej Industries and ITC live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover diagnostics, a diversified group and consumer goods. Suraksha Diagnostic leads on FY26 revenue growth; Godrej Industries leads on FY26 net profit growth and the lowest P/E; ITC leads on FY26 operating margin and Q1 FY27 revenue growth.
Across pathology network, group holding company and FMCG major stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pathology network, group holding company and FMCG major stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Pathology Network, Group Holding Company and FMCG Major Stocks
Which are the best pathology network, group holding company and FMCG major stocks in India with a strong roadmap?
Ans. Suraksha Diagnostic, Godrej Industries and ITC stand out for their roadmaps in diagnostics, a diversified group and consumer goods. FY26 revenue growth was 22.5% at Suraksha Diagnostic, 18.5% at Godrej Industries and 4.4% at ITC, and return on equity ranges from 11.10% to 28.53%.
Is Suraksha Diagnostic a good stock to buy now?
Ans. Suraksha Diagnostic has a debt to equity ratio of 0.53, a return on equity of 13.15% and a P/E of 46.05 against an industry P/E of 62.79. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Suraksha Diagnostic, Godrej Industries and ITC?
Ans. The P/E ratio is 46.05 for Suraksha Diagnostic (industry 62.79), 15.29 for Godrej Industries (industry 36.60) and 15.77 for ITC (industry 34.85). All of them trade below the industry multiple.
Which of these pathology network, group holding company and FMCG major stocks has the highest return on equity?
Ans. ITC has the highest return on equity at 28.53%, followed by Suraksha Diagnostic at 13.15% and Godrej Industries at 11.10%.
What are the risks of investing in pathology network, group holding company and FMCG major stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Suraksha Diagnostic, Godrej Industries and ITC perform in Q1 FY27?
Ans. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore. Godrej Industries reported revenue of Rs 6,360.30 crore, up 11.2% year on year. ITC reported revenue of Rs 30,179.01 crore, up 26.7% year on year.
Do pathology network, group holding company and FMCG major stocks pay dividends?
Ans. Suraksha Diagnostic pays dividends. The dividend yield is 0.02% for Suraksha Diagnostic, based on dividends declared for FY26.
How can I invest in pathology network, group holding company and FMCG major stocks in India?
Ans. You can buy pathology network, group holding company and FMCG major stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
